within Pharmacolibrary.Drugs.ATC.V;

model V09HA02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 370 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09HA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Technetium (99mTc) exametazime labelled cells are autologous white blood cells (typically leukocytes) that are labelled ex vivo with the radiotracer 99mTc-exametazime. The resulting radiolabelled cells are used for radionuclide imaging, particularly to detect sites of infection or inflammation in nuclear medicine diagnostics. The product is approved for clinical use in many countries as a radiopharmaceutical.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic model parameters for technetium (99mTc) exametazime labelled cells in humans were found. However, after intravenous administration of labelled cells, activity is seen initially in the lungs, then redistribution occurs with uptake in the liver, spleen, and bone marrow. Parameters below are rough estimates based on analogous labelled cell imaging agents and clinical practice.</p><h4>References</h4><ol><li><p>Detante, O, et al., &amp; Remy, C (2009). Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. <i>Cell transplantation</i> 18(12) 1369–1379. DOI:<a href=&quot;https://doi.org/10.3727/096368909X474230&quot;>10.3727/096368909X474230</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19849895/&quot;>https://pubmed.ncbi.nlm.nih.gov/19849895</a></p></li><li><p>Goins, B, et al., &amp; Klipper, R (1996). Blood-pool imaging using technetium-99m-labeled liposomes. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 37(8) 1374–1379. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8708778/&quot;>https://pubmed.ncbi.nlm.nih.gov/8708778</a></p></li><li><p>Meseguer-Olmo, L, et al., &amp; Fuente, T (2017). Intraarticular and intravenous administration of . <i>Nuclear medicine and biology</i> 46 36–42. DOI:<a href=&quot;https://doi.org/10.1016/j.nucmedbio.2016.12.003&quot;>10.1016/j.nucmedbio.2016.12.003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28013120/&quot;>https://pubmed.ncbi.nlm.nih.gov/28013120</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09HA02;
